State Street
TXG icon

State Street’s 10x Genomics TXG Stock Holding History

State Street’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Buy
2,801,437
+212,642
+8% +$5.57M ﹤0.01% 1446
2026
Q1 		$55M Buy
2,588,795
+76,276
+3% +$1.52M ﹤0.01% 1690
2025
Q4 		$41M Sell
2,512,519
-7,680
-0.3% -$116K ﹤0.01% 1852
2025
Q3 		$29.5M Buy
2,520,199
+27,523
+1% +$359K ﹤0.01% 2027
2025
Q2 		$28.9M Buy
2,492,676
+680,475
+38% +$6.2M ﹤0.01% 1981
2025
Q1 		$15.8M Buy
1,812,201
+37,209
+2% +$469K ﹤0.01% 2265
2024
Q4 		$25.5M Buy
1,774,992
+24,349
+1% +$384K ﹤0.01% 2089
2024
Q3 		$39.5M Buy
1,750,643
+116,534
+7% +$2.41M ﹤0.01% 1823
2024
Q2 		$31.8M Buy
1,634,109
+48,407
+3% +$1.27M ﹤0.01% 1903
2024
Q1 		$59.5M Buy
1,585,702
+26,474
+2% +$1.16M ﹤0.01% 1631
2023
Q4 		$87.3M Buy
1,559,228
+98,591
+7% +$4.29M ﹤0.01% 1383
2023
Q3 		$60.3M Buy
1,460,637
+28,100
+2% +$1.46M ﹤0.01% 1505
2023
Q2 		$80M Buy
1,432,537
+20,190
+1% +$1.09M ﹤0.01% 1370
2023
Q1 		$78.8M Buy
1,412,347
+66,598
+5% +$3.11M ﹤0.01% 1350
2022
Q4 		$49M Sell
1,345,749
-18,168
-1% -$594K ﹤0.01% 1655
2022
Q3 		$38.8M Buy
1,363,917
+26,695
+2% +$1.02M ﹤0.01% 1783
2022
Q2 		$60.5M Sell
1,337,222
-345,543
-21% -$17.9M ﹤0.01% 1501
2022
Q1 		$128M Buy
1,682,765
+16,343
+1% +$1.43M 0.01% 1121
2021
Q4 		$248M Sell
1,666,422
-1,214
-0.1% -$186K 0.01% 760
2021
Q3 		$243M Buy
1,667,636
+73,616
+5% +$12.6M 0.01% 742
2021
Q2 		$312M Buy
1,594,020
+463,597
+41% +$83.9M 0.02% 668
2021
Q1 		$205M Buy
1,130,423
+58,876
+5% +$10.2M 0.01% 792
2020
Q4 		$152M Buy
1,071,547
+508,153
+90% +$73.7M 0.01% 877
2020
Q3 		$70.2M Buy
563,394
+71,404
+15% +$7.5M ﹤0.01% 1202
2020
Q2 		$43.9M Buy
491,990
+484,890
+6,829% +$37.8M ﹤0.01% 1537
2020
Q1 		$442K Buy
7,100
+2,400
+51% +$187K ﹤0.01% 3471
2019
Q4 		$358K Buy
+4,700
New +$283K ﹤0.01% 3566

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street's TXG Position: Q2 2026 in Review

State Street increased its 10x Genomics (TXG) stake by 8.2% in Q2 2026, buying an estimated $5.57M and bringing the position to 2,801,437 shares worth $107M. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

State Street first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $312M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • State Street held 2,801,437 shares of 10x Genomics worth $107M as of Q2 2026.
  • State Street bought 212,642 10x Genomics shares in Q2 2026, an estimated $5.57M.
  • 10x Genomics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1446 holding.
  • State Street first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • State Street's 10x Genomics position peaked at $312M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.